Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398890 | 0.88 | LMNA (0.40) | LMNACYP2C19TDP1ALDH1A1 | |
| SCHEMBL8816418 | 0.83 | LMNA (0.40) | LMNACYP2C19 | |
| SCHEMBL19379179 | 0.81 | GAA (0.39) | LMNACYP2C19TSHRTDP1ALDH1A1 | |
| SCHEMBL8155340 | 0.81 | TSHR (0.37) | TSHRTDP1 | |
| SCHEMBL8373916 | 0.81 | TSHR (0.37) | TSHRTDP1 | |
| SCHEMBL8372103 | 0.81 | TSHR (0.37) | TSHRTDP1 | |
| SCHEMBL11430387 | 0.79 | LMNA (0.61) | LMNACYP2C19TSHRTDP1ALDH1A1 | |
| SCHEMBL8817881 | 0.79 | LMNA (0.37) | LMNACYP2C19 | |
| SCHEMBL8816553 | 0.76 | LMNA (0.71) | LMNACYP2C19ALDH1A1 | |
| SCHEMBL19398512 | 0.72 | LMNA (0.39) | LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275311-A1 | NON-AQUEOUS LIQUID ELECTROLYTE, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHORUS COMPOUND USED THEREIN | UBE INDUSTRIES, LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| WO-1997039756-A1 | USE OF PHOSPHONIC ACID ESTERS FOR THE TREATMENT OF FUNCTIONAL DISORDERS OF THE BRAIN AND DEPRESSION | TROPONWERKE GMBH & CO. KG (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275311-A1 | NON-AQUEOUS LIQUID ELECTROLYTE, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHORUS COMPOUND USED THEREIN | SCN10A, CACNA2D4, P2RY10 | LMNA 1341/4885CYP2C19 3584/4885TSHR 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.